Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.90M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.01M
Average 0.05M
XLO Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Xilio Therapeutics, Inc.NASDAQ: XLO
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow growth accelerates
Q1 FY2026 investing cash flow of $556K (cash outflow) rose 2427.3% year over year, ahead of the +1713.8% change in trailing-twelve-month investing cash flow. Sequentially, it rose 485.3% from the prior quarter. Over 3 fiscal years it compounded at -34.8% a year.
Context
- Investing cash flow amounted to 1.2% of revenue in FY2025, up 0.6 pp from a year earlier.
- Investing cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +2427.3% holds above the trailing-twelve-month pace of +1713.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (518K) USD
- Year-over-year change
- -1338.9%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (518K) | -1338.9% |
| FY2024 | 2024-12-31 | (36K) | +92.6% |
| FY2023 | 2023-12-31 | (486K) | +74.0% |
| FY2022 | 2022-12-31 | (1.87M) | -69.7% |
| FY2021 | 2021-12-31 | (1.1M) | — |
Investing Cash Flow vs competitors
How XLO compares with its peers on the latest reported figures
- XLO's LTM Mar 2026 investing cash flow of $1.05M is the largest of the 4 companies compared; the peer median is $33K.
- Its year-over-year change of +1713.8% is the highest of 3, against a peer median of +0.0%.
- Investing cash flow amounts to 2.0% of revenue for XLO, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.05M | +1713.8% | -34.8% | 2.0% | |
| LTM Jun 2026 | $584K | — | -34.3% | 1.7% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $33K | -99.9% | -65.6% | — |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| Peer median (excluding XLO) | $33K | +0.0% | -49.9% | 1.7% | |
Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| Deferred Income Tax | 222K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.96M | 8.42M | 7.38M | 6.43M | 6.94M |
| Change in Working Capital | (11.8M) | 2M | (1.66M) | 31.78M | 25.13M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.82M) | 485K | (2.06M) | 1.53M | 152K |
| Other Working Capital | (8.99M) | 1.52M | 405K | 30.26M | 29.97M |
| Other Non-Cash Items | 173K | 224K | 160K | 3K | (3.56M) |
| Operating Cash Flow | (80.75M) | (75.72M) | (68.62M) | (18.38M) | (4.99M) |
| Capital Expenditures | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.1M) | (1.87M) | (486K) | (36K) | (518K) |
| Debt Repayment | (110K) | (85K) | (6.75M) | (3.38M) | 0 |
| Common Stock Issued | 116.36M | 16K | 202K | 6.83M | 87.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (467K) | 0 | 0 | 25.75M | 0 |
| Financing Cash Flow | 260.67M | (69K) | (6.55M) | 29.2M | 87.78M |
| Effect of Forex Changes | 0 | (9K) | (25K) | 0 | 0 |
| Net Change in Cash | 178.82M | (77.67M) | (75.68M) | 10.78M | 82.27M |
| Free Cash Flow | (81.85M) | (77.59M) | (69.11M) | (18.41M) | (5.51M) |
Xilio Therapeutics, Inc.
NASDAQ:XLO
Intrinsic Alpha fair value
Locked
Current Price
$7.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.